HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.

Abstract
Alzheimer's disease (AD) is a highly prevalent disorder for which there are no effective therapies. Accumulation of amyloid β (Aβ) peptides in the brain is associated with impaired cognition and memory, pronounced inflammatory dysregulation, and subsequent amyloid plaque deposition. Thus, drugs that promote the clearance of Aβ peptides and resolution of inflammation may represent viable therapeutic approaches. Agonists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive impairment and amyloid accumulation in murine models of AD. The use of an agonist to the nuclear receptor RXR, bexarotene, as monotherapy against AD, presents potential challenges due to the metabolic perturbations it induces in the periphery, most prominently hypertriglyceridemia. We report that the ω-3 fatty acid docosahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Aβ, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD. Moreover, DHA abrogates bexarotene-induced hypertriglyceridemia in vivo. Importantly, dual therapy promotes reductions in AD pathology and resultant amelioration of cognitive deficits. While monotherapy with either bexarotene or DHA resulted in modest effects in vitro and in vivo, combined treatment with both agents produced a significant additive benefit on associated AD-related phenotypes, suggesting that targeted combinatorial agents may be beneficial over single agents alone in treating AD.
AuthorsBrad T Casali, Angela W Corona, Monica M Mariani, J Colleen Karlo, Kaushik Ghosal, Gary E Landreth
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience (J Neurosci) Vol. 35 Issue 24 Pg. 9173-81 (Jun 17 2015) ISSN: 1529-2401 [Electronic] United States
PMID26085639 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2015 the authors 0270-6474/15/359173-09$15.00/0.
Chemical References
  • Fatty Acids, Omega-3
  • Receptors, Cytoplasmic and Nuclear
  • Tetrahydronaphthalenes
  • Docosahexaenoic Acids
  • Bexarotene
Topics
  • Alzheimer Disease (drug therapy, metabolism, pathology)
  • Animals
  • Bexarotene
  • Brain (drug effects, metabolism, pathology)
  • Cells, Cultured
  • Disease Models, Animal
  • Docosahexaenoic Acids (administration & dosage)
  • Drug Therapy, Combination
  • Fatty Acids, Omega-3 (administration & dosage)
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Receptors, Cytoplasmic and Nuclear (agonists, metabolism)
  • Tetrahydronaphthalenes (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: